| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ARTICLES |
Departments of Urologic Surgery (J.Z., T.Z.T., S.K., R.J.M.) and Cell Biology (J.Z., S.K., R.J.M.), The Vanderbilt Prostate Cancer Center (J.Z., T.Z.T., S.K., R.J.M.), Center for Reproductive Biology Research (R.J.M.), and The Vanderbilt-Ingram Cancer Center (R.J.M.), Nashville, Tennessee 37232
Address all correspondence and requests for reprints to: Dr. Robert J. Matusik, Department of Urologic Surgery, A-1302 Medical Center North, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765. E-mail: robert.matusik{at}mcmail.vanderbilt.edu
Transient transfection studies have shown that the probasin (PB) promoter confers androgen selectivity over other steroid hormones, and transgenic animal studies have demonstrated that the PB promoter will target androgen, but not glucocorticoid, regulation in a prostate-specific manner. Previous PB promoters either targeted low levels of transgene expression or became too large to be conveniently used. The goal was to design a PB promoter that would be small, yet target high levels of prostate-specific transgene expression. Thus, a composite probasin promoter (ARR2PB) coupled to the bacterial chloramphenicol acetyltransferase reporter (ARR2PBCAT) was generated and tested in prostatic and nonprostatic cell lines and in a transgenic mouse model. In PC-3, LNCaP, and DU145 prostate cancer cell lines, the ARR2PB promoter gave basal expression and was induced in response to androgen and glucocorticoid treatment after cotransfection with the respective steroid receptor. Basal expression of ARR2PBCAT in the nonprostatic COS-1, MCF-7, ZR-75–1, and PANC-1 cell lines was very low; however, CAT activity could be induced in response to androgens and glucocorticoids when cells were cotransfected with either the AR or GR. In contrast to the transfection studies, ARR2PBCAT transgene expression remained highly specific for prostatic epithelium in transgenic mice. CAT activity decreased after castration, and could be induced by androgens and, in addition, glucocorticoids. This demonstrates that the necessary sequences required to target prostate-specific epithelial expression are contained within the composite ARR2PB minimal promoter, and that high transgene expression can now be regulated by both androgens and glucocorticoids. The ARR2PB promoter represents a novel glucocorticoid inducible promoter that can be used for the generation of transgenic mouse models and in viral gene therapy vectors for the treatment of prostate cancer in humans.
This article has been cited by other articles:
 |
|
 |
|
  S. Shin, T.-D. Kim, F. Jin, J. M. van Deursen, S. M. Dehm, D. J. Tindall, J. P. Grande, J.-M. Munz, G. Vasmatzis, and R. Janknecht Induction of Prostatic Intraepithelial Neoplasia and Modulation of Androgen Receptor by ETS Variant 1/ETS-Related Protein 81 Cancer Res., October 15, 2009; 69(20): 8102 - 8110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zong, L. Xin, A. S. Goldstein, D. A. Lawson, M. A. Teitell, and O. N. Witte ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells PNAS, July 28, 2009; 106(30): 12465 - 12470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bai, E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen From the Cover: Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice PNAS, September 2, 2008; 105(35): 13003 - 13008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Teyssier, S. Bianco, O. Lanvin, and J.-M. Vanacker The orphan receptor ERR{alpha} interferes with steroid signaling Nucleic Acids Res., September 1, 2008; 36(16): 5350 - 5361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Jin, Y. Lho, L. Connelly, Y. Wang, X. Yu, L. Saint Jean, T. C. Case, K. Ellwood-Yen, C. L. Sawyers, N. A. Bhowmick, et al. The Nuclear Factor-{kappa}B Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth Cancer Res., August 15, 2008; 68(16): 6762 - 6769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nardella, Z. Chen, L. Salmena, A. Carracedo, A. Alimonti, A. Egia, B. Carver, W. Gerald, C. Cordon-Cardo, and P. P. Pandolfi Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events Genes & Dev., August 15, 2008; 22(16): 2172 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. Q. Mo, Q. Hu, G. Boivin, L. Levin, S. Lu, D. Yang, Z. Dong, and S. Lu Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer Cancer Res., August 1, 2008; 68(15): 6396 - 6406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Klezovitch, M. Risk, I. Coleman, J. M. Lucas, M. Null, L. D. True, P. S. Nelson, and V. Vasioukhin A causal role for ERG in neoplastic transformation of prostate epithelium PNAS, February 12, 2008; 105(6): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-P. Liao, C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al. Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence Cancer Res., August 1, 2007; 67(15): 7525 - 7533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Simanainen, C. M. Allan, P. Lim, S. McPherson, M. Jimenez, J. D. Zajac, R. A. Davey, and D. J. Handelsman Disruption of Prostate Epithelial Androgen Receptor Impedes Prostate Lobe-Specific Growth and Function Endocrinology, May 1, 2007; 148(5): 2264 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Butcher, N. L. Tetlow, C. Cheung, G. M. Broadhurst, and R. F. Minchin Induction of Human Arylamine N-Acetyltransferase Type I by Androgens in Human Prostate Cancer Cells Cancer Res., January 1, 2007; 67(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ellwood-Yen, J. Wongvipat, and C. Sawyers Transgenic Mouse Model for Rapid Pharmacodynamic Evaluation of Antiandrogens Cancer Res., November 1, 2006; 66(21): 10513 - 10516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yu, K. Suzuki, Y. Wang, A. Gupta, R. Jin, M.-C. Orgebin-Crist, and R. Matusik The Role of Forkhead Box A2 to Restrict Androgen-Regulated Gene Expression of Lipocalin 5 in the Mouse Epididymis Mol. Endocrinol., October 1, 2006; 20(10): 2418 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dai, O. Kim, Y. Xie, Z. Guo, K. Xu, B. Wang, X. Kong, J. Melamed, H. Chen, C. J. Bieberich, et al. Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse Cancer Res., August 15, 2006; 66(16): 8058 - 8064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Seethammagari, X. Xie, N. M. Greenberg, and D. M. Spencer EZC-Prostate Models Offer High Sensitivity and Specificity for Noninvasive Imaging of Prostate Cancer Progression and Androgen Receptor Action. Cancer Res., June 15, 2006; 66(12): 6199 - 6209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhong, G. Saribekyan, C.-P. Liao, M. B. Cohen, and P. Roy-Burman Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis Cancer Res., February 15, 2006; 66(4): 2188 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Watson, K. Ellwood-Yen, J. C. King, J. Wongvipat, M. M. LeBeau, and C. L. Sawyers Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell Line Cancer Res., December 15, 2005; 65(24): 11565 - 11571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Lamb and L. Zhang Challenges in Prostate Cancer Research: Animal Models for Nutritional Studies of Chemoprevention and Disease Progression J. Nutr., December 1, 2005; 135(12): 3009S - 3015S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hill, Y. Song, R. D. Cardiff, and T. Van Dyke Heterogeneous Tumor Evolution Initiated by Loss of pRb Function in a Preclinical Prostate Cancer Model Cancer Res., November 15, 2005; 65(22): 10243 - 10254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-L Hsieh, Z Xie, Z-Y Liu, J E Green, W D Martin, M W Datta, F Yeung, D Pan, and L W K Chung A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals J. Mol. Endocrinol., October 1, 2005; 35(2): 293 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ye, S. J. Han, S. Y. Tsai, F. J. DeMayo, J. Xu, M.-J. Tsai, and B. W. O'Malley Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice PNAS, July 5, 2005; 102(27): 9487 - 9492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Link, C. J. Burd, E. Williams, T. Marshall, G. Rosson, E. Henry, B. Weissman, and K. E. Knudsen BAF57 Governs Androgen Receptor Action and Androgen-Dependent Proliferation through SWI/SNF Mol. Cell. Biol., March 15, 2005; 25(6): 2200 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Jin, Y. Wang, N. Masumori, K. Ishii, T. Tsukamoto, S. B. Shappell, S. W. Hayward, S. Kasper, and R. J. Matusik NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice Cancer Res., August 1, 2004; 64(15): 5489 - 5495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-N. Song, M. Coghlan, and E. P. Gelmann Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor Mol. Endocrinol., January 1, 2004; 18(1): 70 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, N. Gao, S. Kasper, K. Reid, C. Nelson, and R. J. Matusik An Androgen-Dependent Upstream Enhancer Is Essential for High Levels of Probasin Gene Expression Endocrinology, January 1, 2004; 145(1): 134 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Freeman, B. E. Welm, R. D. Gangula, J. M. Rosen, M. Ittmann, N. M. Greenberg, and D. M. Spencer Inducible Prostate Intraepithelial Neoplasia with Reversible Hyperplasia in Conditional FGFR1-Expressing Mice Cancer Res., December 1, 2003; 63(23): 8256 - 8263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kakinuma, E. R. Bergert, C. Spitzweg, J. C. Cheville, M. M. Lieber, and J. C. Morris Probasin Promoter (ARR2PB)-Driven, Prostate-Specific Expression of the Human Sodium Iodide Symporter (h-NIS) for Targeted Radioiodine Therapy of Prostate Cancer Cancer Res., November 15, 2003; 63(22): 7840 - 7844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Marshall, K. A. Link, C. E. Petre-Draviam, and K. E. Knudsen Differential Requirement of SWI/SNF for Androgen Receptor Activity J. Biol. Chem., August 15, 2003; 278(33): 30605 - 30613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Gao, J. Zhang, M. A. Rao, T. C. Case, J. Mirosevich, Y. Wang, R. Jin, A. Gupta, P. S. Rennie, and R. J. Matusik The Role of Hepatocyte Nuclear Factor-3{alpha} (Forkhead Box A1) and Androgen Receptor in Transcriptional Regulation of Prostatic Genes Mol. Endocrinol., August 1, 2003; 17(8): 1484 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-H. Shim, L. Johnson, H.-L. Noh, Y.-J. Kim, H. Sun, C. Zeiss, and H. Zhang Expression of the F-Box Protein SKP2 Induces Hyperplasia, Dysplasia, and Low-Grade Carcinoma in the Mouse Prostate Cancer Res., April 1, 2003; 63(7): 1583 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Logg, A. Logg, R. J. Matusik, B. H. Bochner, and N. Kasahara Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector J. Virol., November 13, 2002; 76(24): 12783 - 12791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Song, X. Wu, W. C. Powell, R. D. Cardiff, M. B. Cohen, R. T. Tin, R. J. Matusik, G. J. Miller, and P. Roy-Burman Fibroblast Growth Factor 8 Isoform b Overexpression in Prostate Epithelium: A New Mouse Model for Prostatic Intraepithelial Neoplasia Cancer Res., September 1, 2002; 62(17): 5096 - 5105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dotzlaw, U. Moehren, S. Mink, A. C. B. Cato, J. A. Iniguez Lluhi, and A. Baniahmad The Amino Terminus of the Human AR Is Target for Corepressor Action and Antihormone Agonism Mol. Endocrinol., April 1, 2002; 16(4): 661 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Andriani, B. Nan, J. Yu, X. Li, N. L. Weigel, M. J. McPhaul, S. Kasper, S. Kagawa, B. Fang, R. J. Matusik, et al. Use of the Probasin Promoter ARR2PB to Express Bax in Androgen Receptor-Positive Prostate Cancer Cells J Natl Cancer Inst, September 5, 2001; 93(17): 1314 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xie, X. Zhao, Y. Liu, J. Zhang, R. J. Matusik, K. M. Slawin, and D. M. Spencer Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer Cancer Res., September 1, 2001; 61(18): 6795 - 6804. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
